Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics

Min Hee Lee, Amit Sharma, Min Jung Chang, Jinju Lee, Subin Son, Jonathan L. Sessler, Chulhun Kang, Jong Seung Kim

Research output: Contribution to journalReview article

86 Citations (Scopus)

Abstract

Theranostic systems are receiving ever-increasing attention due to their potential therapeutic utility, imaging enhancement capability, and promise for advancing the field of personalized medicine, particularly as it relates to the diagnosis, staging, and treatment of cancer. In this Tutorial Review, we provide an introduction to the concepts of theranostic drug delivery effected via use of conjugates that are able to target cancer cells selectively, provide cytotoxic chemotherapeutics, and produce readily monitored imaging signals in vitro and in vivo. The underlying design concepts, requiring the synthesis of conjugates composed of imaging reporters, masked chemotherapeutic drugs, cleavable linkers, and cancer targeting ligands, are discussed. Particular emphasis is placed on highlighting the potential benefits of fluorogenic reaction-based targeted systems that are activated for both imaging and therapy by cellular entities, e.g., thiols, reactive oxygen species and enzymes, which are present at relatively elevated levels in tumour environments, physiological characteristics of cancer, e.g., hypoxia and acidic pH. Also discussed are systems activated by an external stimulus, such as light. The work summarized in this Tutorial Review will help define the role fluorogenic reaction-based, cancer-targeting theranostics may have in advancing drug discovery efforts, as well as improving our understanding of cellular uptake and drug release mechanisms.

Original languageEnglish
Pages (from-to)28-52
Number of pages25
JournalChemical Society Reviews
Volume47
Issue number1
DOIs
Publication statusPublished - 2018 Jan 7

Fingerprint

Prodrugs
Imaging techniques
Neoplasms
Drug delivery
Precision Medicine
Sulfhydryl Compounds
Pharmaceutical Preparations
Neoplasm Staging
Medicine
Tumors
Reactive Oxygen Species
Drug Discovery
Cells
Ligands
Therapeutics
Theranostic Nanomedicine
Enzymes
Light

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics. / Lee, Min Hee; Sharma, Amit; Chang, Min Jung; Lee, Jinju; Son, Subin; Sessler, Jonathan L.; Kang, Chulhun; Kim, Jong Seung.

In: Chemical Society Reviews, Vol. 47, No. 1, 07.01.2018, p. 28-52.

Research output: Contribution to journalReview article

Lee, MH, Sharma, A, Chang, MJ, Lee, J, Son, S, Sessler, JL, Kang, C & Kim, JS 2018, 'Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics', Chemical Society Reviews, vol. 47, no. 1, pp. 28-52. https://doi.org/10.1039/c7cs00557a
Lee, Min Hee ; Sharma, Amit ; Chang, Min Jung ; Lee, Jinju ; Son, Subin ; Sessler, Jonathan L. ; Kang, Chulhun ; Kim, Jong Seung. / Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics. In: Chemical Society Reviews. 2018 ; Vol. 47, No. 1. pp. 28-52.
@article{05657da8b4d34f8ebcd55a4e8eac5c64,
title = "Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics",
abstract = "Theranostic systems are receiving ever-increasing attention due to their potential therapeutic utility, imaging enhancement capability, and promise for advancing the field of personalized medicine, particularly as it relates to the diagnosis, staging, and treatment of cancer. In this Tutorial Review, we provide an introduction to the concepts of theranostic drug delivery effected via use of conjugates that are able to target cancer cells selectively, provide cytotoxic chemotherapeutics, and produce readily monitored imaging signals in vitro and in vivo. The underlying design concepts, requiring the synthesis of conjugates composed of imaging reporters, masked chemotherapeutic drugs, cleavable linkers, and cancer targeting ligands, are discussed. Particular emphasis is placed on highlighting the potential benefits of fluorogenic reaction-based targeted systems that are activated for both imaging and therapy by cellular entities, e.g., thiols, reactive oxygen species and enzymes, which are present at relatively elevated levels in tumour environments, physiological characteristics of cancer, e.g., hypoxia and acidic pH. Also discussed are systems activated by an external stimulus, such as light. The work summarized in this Tutorial Review will help define the role fluorogenic reaction-based, cancer-targeting theranostics may have in advancing drug discovery efforts, as well as improving our understanding of cellular uptake and drug release mechanisms.",
author = "Lee, {Min Hee} and Amit Sharma and Chang, {Min Jung} and Jinju Lee and Subin Son and Sessler, {Jonathan L.} and Chulhun Kang and Kim, {Jong Seung}",
year = "2018",
month = "1",
day = "7",
doi = "10.1039/c7cs00557a",
language = "English",
volume = "47",
pages = "28--52",
journal = "Chemical Society Reviews",
issn = "0306-0012",
publisher = "Royal Society of Chemistry",
number = "1",

}

TY - JOUR

T1 - Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics

AU - Lee, Min Hee

AU - Sharma, Amit

AU - Chang, Min Jung

AU - Lee, Jinju

AU - Son, Subin

AU - Sessler, Jonathan L.

AU - Kang, Chulhun

AU - Kim, Jong Seung

PY - 2018/1/7

Y1 - 2018/1/7

N2 - Theranostic systems are receiving ever-increasing attention due to their potential therapeutic utility, imaging enhancement capability, and promise for advancing the field of personalized medicine, particularly as it relates to the diagnosis, staging, and treatment of cancer. In this Tutorial Review, we provide an introduction to the concepts of theranostic drug delivery effected via use of conjugates that are able to target cancer cells selectively, provide cytotoxic chemotherapeutics, and produce readily monitored imaging signals in vitro and in vivo. The underlying design concepts, requiring the synthesis of conjugates composed of imaging reporters, masked chemotherapeutic drugs, cleavable linkers, and cancer targeting ligands, are discussed. Particular emphasis is placed on highlighting the potential benefits of fluorogenic reaction-based targeted systems that are activated for both imaging and therapy by cellular entities, e.g., thiols, reactive oxygen species and enzymes, which are present at relatively elevated levels in tumour environments, physiological characteristics of cancer, e.g., hypoxia and acidic pH. Also discussed are systems activated by an external stimulus, such as light. The work summarized in this Tutorial Review will help define the role fluorogenic reaction-based, cancer-targeting theranostics may have in advancing drug discovery efforts, as well as improving our understanding of cellular uptake and drug release mechanisms.

AB - Theranostic systems are receiving ever-increasing attention due to their potential therapeutic utility, imaging enhancement capability, and promise for advancing the field of personalized medicine, particularly as it relates to the diagnosis, staging, and treatment of cancer. In this Tutorial Review, we provide an introduction to the concepts of theranostic drug delivery effected via use of conjugates that are able to target cancer cells selectively, provide cytotoxic chemotherapeutics, and produce readily monitored imaging signals in vitro and in vivo. The underlying design concepts, requiring the synthesis of conjugates composed of imaging reporters, masked chemotherapeutic drugs, cleavable linkers, and cancer targeting ligands, are discussed. Particular emphasis is placed on highlighting the potential benefits of fluorogenic reaction-based targeted systems that are activated for both imaging and therapy by cellular entities, e.g., thiols, reactive oxygen species and enzymes, which are present at relatively elevated levels in tumour environments, physiological characteristics of cancer, e.g., hypoxia and acidic pH. Also discussed are systems activated by an external stimulus, such as light. The work summarized in this Tutorial Review will help define the role fluorogenic reaction-based, cancer-targeting theranostics may have in advancing drug discovery efforts, as well as improving our understanding of cellular uptake and drug release mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=85040229435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040229435&partnerID=8YFLogxK

U2 - 10.1039/c7cs00557a

DO - 10.1039/c7cs00557a

M3 - Review article

C2 - 29057403

AN - SCOPUS:85040229435

VL - 47

SP - 28

EP - 52

JO - Chemical Society Reviews

JF - Chemical Society Reviews

SN - 0306-0012

IS - 1

ER -